Celcuity (CELC) vs Clover Health Investments (CLOV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Clover Health Investments (CLOV) has outperformed Celcuity (CELC) over the past year, gaining 68.9% versus a gain of 33.7%. Over five years, CELC leads with a +261.4% price change compared with -42.4% for CLOV. Celcuity is the larger company by market cap ($3.22 billion vs $2.42 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELC | CLOV |
|---|---|---|
| Share price | $65.78 | $4.56 |
| Market cap | $3.22B | $2.42B |
| 1-day change | -7.68% | -0.87% |
| YTD return | -34.05% | +94.04% |
| 1-year return | +33.66% | +68.89% |
| 5-year return | +261.43% | -42.35% |
| Forward P/E | — | 30.40 |
| EPS (TTM) | $-4.31 | $-0.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.92B |
| Revenue growth (YoY) | — | +40.34% |
| Net income (latest FY) | $-177.04M | $-85.55M |
| Operating margin | — | -4.44% |
| Net margin | — | -4.45% |
| 52-week high | $151.02 | $5.59 |
| 52-week low | $45.03 | $1.58 |
| Distance from 52-week high | -56.44% | -18.43% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +138.54% | +17.98% |
| Average volume | 1.18M | 4.27M |
| Shares outstanding | 48.93M | 435.44M |
| Employees | 155 | 724 |
| Sector | Health Care | Healthcare |
| Industry | Medical Specialities | Healthcare Plans |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLOV has outperformed CELC by 35.2 percentage points over the past year.
- The two companies sit in different sectors: Celcuity in Health Care and Clover Health Investments in Healthcare.
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
About Clover Health Investments
CLOV stock →Clover Health Investments, Corp. provides medicare advantage plans in the United States.
Healthcare · Healthcare Plans · 724 employees
CELC vs CLOV FAQ
Which is bigger, Celcuity or Clover Health Investments?
Celcuity (CELC) is larger, with a market capitalization of $3.22B compared with $2.42B for Clover Health Investments (CLOV).
Which stock has performed better over the past year, CELC or CLOV?
CLOV returned +68.89% over the past 12 months, compared with +33.66% for CELC (price return, excluding dividends). Past performance does not predict future results.
Are Celcuity and Clover Health Investments in the same industry?
No. Celcuity is in the Health Care sector, while Clover Health Investments is in Healthcare.